본문 바로가기
KERD
논문KCI 등재

소아청소년 코로나바이러스감염증-19의 치료: 치료 약제를 중심으로

Therapeutics in the Treatment of COVID-19 for Children and Adolescents

최재홍|윤기욱|최수한
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)|2022.04|Pediatric Infection and Vaccine|제29권 제1호|pp. 1-15|DOI 10.14776/piv.2022.29.e1

1

조회

0

다운로드

2

인용

0

참고문헌

키워드

COVID-19AdolescentChildTherapeutics

초록

소아청소년에서 코로나바이러스감염증-19 (coronavirus disease 2019 [COVID-19])은 대부분 경증이며 특별한 치료없이호전될 수 있다. 하지만 일부 소아청소년 COVID-19 환자에서는 중증 또는 위중증으로 진행할 수 있다. 소아청소년 COVID-19 치료 약제에 대한 임상 데이터는 제한적이지만, 중증 및 위중증 COVID-19 소아청소년 환자에서 사용 가능한 약제들은 있다. 본 종설에서는 COVID-19 치료 약제 중 항바이러스제와 면역조절제에 중점을 두고 임상 데이터와 소아청소년에 대한 권고사항들을 논의하였다.

Abstract

Coronavirus disease 2019 (COVID-19) presents as a mild-to-moderate respiratory illness in most children. However, a small proportion of children with COVID-19 develop severe or critical illnesses. Although pediatric clinical trials for the treatment of COVID-19 are sparse, some drugs are available for children and adolescents with severe COVID-19. This review summarizes clinical data focusing on antiviral agents and immunomodulators for use in treating COVID-19. In addition, current recommendations for therapeutics for children and adolescents with COVID-19 are discussed.

참고문헌 (51)

  1. Fraile Navarro D, "Clinical care of children and adolescents with COVID-19 : recommendations from the National COVID-19 Clinical Evidence Taskforce", Med J Aust (2021)
  2. Hyunju Lee, "Analysis of Critical COVID-19 Cases Among Children in Korea", Journal of Korean Medical Science, 37(1), pp.1~10 (2022), 대한의학회[DOI]
  3. Woodruff RC, "Risk factors for severe COVID-19 in children", Pediatrics (2021)
  4. Kompaniyets L, "Underlying medical conditions associated with severe COVID-19 illness among children", JAMA Netw Open, 4, pp.e2111182~ (2021)
  5. Chiotos K, "Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019", severe acute respiratory syndrome coronavirus 2, 2021, pp.10, 34~48
  6. Dulek DE, "Multidisciplinary guidance regarding the use of immunomodulatory therapies for acute coronavirus disease 2019 in pediatric patients", J Pediatric Infect Dis Soc, 9, pp.716~737 (2020)
  7. "COVID-19 rapid guideline: managing COVID-19" (2021)[URL]
  8. "Coronavirus disease 2019 (COVID-19) treatment guidelines" (2022)[URL]
  9. "Therapeutics and COVID-19: living guideline" (2022)[URL]
  10. "IDSA guidelines on the treatment and management of patients with COVID-19" (2022)[URL]
  11. Hall MD, "Report of the National Institutes of Health SARS-CoV-2 antiviral therapeutics summit", J Infect Dis, 224, pp.S1~21 (2021)
  12. WHO Solidarity Trial Consortium, "Repurposed antiviral drugs for COVID-19-Interim WHO Solidarity Trial results", N Engl J Med, 384, pp.497~511 (2021)
  13. Beigel JH, "Remdesivir for the treatment of COVID-19-final report", N Engl J Med, 383, pp.1813~1826 (2020)
  14. Spinner CD, "Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19 : a randomized clinical trial", JAMA, 324, pp.1048~1057 (2020)
  15. Goldman JD, "Remdesivir for 5 or 10 days in patients with severe COVID-19", N Engl J Med, 383, pp.1827~1837 (2020)
  16. Gottlieb RL, "Early remdesivir to prevent progression to severe COVID-19 in outpatients", N Engl J Med, 386, pp.305~315 (2022)
  17. "Gilead Sciences. Study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of remdesivir (GS-5734™) in participants from birth to < 18 years of age with coronavirus disease 2019 (COVID-19) (CARAVAN)" (2021)[URL]
  18. Goldman DL, "Compassionate use of remdesivir in children with severe COVID-19", Pediatrics, 147, pp.e2020047803~ (2021)
  19. Méndez-Echevarría A, "Compassionate use of remdesivir in children with COVID-19", Eur J Pediatr, 180, pp.1317~1322 (2021)
  20. "Australian guidelines for the clinical care of people with COVID-19" (2022)[URL]
  21. "FDA takes actions to expand use of treatment for outpatients with mild-to-moderate COVID-19" (2022)[URL]
  22. "Coronavirus disease 2019 (COVID-19) treatment guidelines. Special considerations in children" (2021)[URL]
  23. "Guidance on the use of COVID-19 treatment" (2022)[URL]
  24. "Changes in the approval of remdesivir" (2022)[URL]
  25. "Approval for additional emergency use of remdesivir" (2022)[URL]
  26. "Fact sheet for healthcare providers: emergency use authorization for paxlovid" (2021)[URL]
  27. Pourkarim F, "Molnupiravir : a new candidate for COVID-19 treatment", Pharmacol Res Perspect, 10, pp.e00909~ (2022)
  28. Jayk Bernal A, "Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients", N Engl J Med, 386, pp.509~520 (2022)
  29. "Fact sheet for healthcare providers: emergency use authorization for molnupiravir" (2021)[URL]
  30. Mehta P, "COVID-19 : consider cytokine storm syndromes and immunosuppression", Lancet, 395, pp.1033~1034 (2020)
  31. Angus DC, "Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19 : the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial", JAMA, 324, pp.1317~1329 (2020)
  32. Dequin PF, "Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19 : a randomized clinical trial", JAMA, 324, pp.1298~1306 (2020)
  33. WHO Rapid Evidence Appraisal for COVID-19 Therapies(REACT)Working Group, "Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19 : a meta-analysis", JAMA, 324, pp.1330~1341 (2020)
  34. Tomazini BM, "Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19 : the CoDEX randomized clinical trial", JAMA, 324, pp.1307~1316 (2020)
  35. RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with COVID-19", N Engl J Med, 384, pp.693~704 (2021)
  36. Jeronimo CM, "Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019(COVID-19; Metcovid) : a randomized, double-blind, phase IIb, placebo-controlled trial", Clin Infect Dis, 72, pp.e373~81 (2021)
  37. "Fact sheet for healthcare providers: emergency use authorization for Actemra (tocilizumab)" (2021)[URL]
  38. RECOVERY Collaborative Group, "Tocilizumab in patients admitted to hospital with COVID-19(RECOVERY) : a randomised, controlled, open-label, platform trial", Lancet, 397, pp.1637~1645 (2021)
  39. WHO Rapid Evidence Appraisal for COVID-19 Therapies(REACT)Working Group, "Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis", JAMA, 326, pp.499~518 (2021)
  40. Kalil AC, "Baricitinib plus remdesivir for hospitalized adults with COVID-19", N Engl J Med, 384, pp.795~807 (2021)
  41. Marconi VC, "Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19(COV-BARRIER) : a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial", Lancet Respir Med, 9, pp.1407~1418 (2021)
  42. "Fact sheet for healthcare providers: emergency use authorization of baricitinib" (2021)[URL]
  43. Dougan M, "A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load", Clin Infect Dis (2021)
  44. Dougan M, "Bamlanivimab plus etesevimab in mild or moderate COVID-19", N Engl J Med, 385, pp.1382~1392 (2021)
  45. Gupta A, "Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab", N Engl J Med, 385, pp.1941~1950 (2021)
  46. Weinreich DM, "REGEN-COV antibody combination and outcomes in outpatients with COVID-19", N Engl J Med, 385, pp.e81~ (2021)
  47. Mak G, "Safety and tolerability of monoclonal antibody therapies for treatment of COVID-19 in pediatric patients", Pediatr Infect Dis J, 40, pp.e507~9 (2021)
  48. "Management of strategies in children and adolescents with mild to moderate COVID-19" (2022)[URL]
  49. "Fact sheet for healthcare providers: emergency use authorization of bamlanivimab and etesevimab" (2021)[URL]
  50. Cameroni E, "Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift", Nature, 602, pp.664~670 (2022)
  51. "Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the Omicron variant" (2022)[URL]

관련 논문AI추천

소아청소년 코로나바이러스감염증-19 대응지침김기환, 김동현, 김종현, 김한울, 박지영, 은병욱, 조대선, 조은영, 최수한, 최은화, 최재홍, 한미선, 대한소아감염학회대한소아감염학회 · Pediatric Infection and Vaccine2020 · 제27권 제1호소아청소년 코로나바이러스감염증-19: 역학과 임상 양상강지만, 김동현, 김한울, 조은영, 최수한대한소아감염학회 · Pediatric Infection and Vaccine2020 · 제27권 제1호코로나바이러스감염증-19: 소아청소년의 임상 경과가 성인에 비하여 양호한 이유곽병옥, 김동현대한소아감염학회 · Pediatric Infection and Vaccine2021 · 제28권 제1호코로나바이러스 감염증-19 백신에 대한 업데이트 및 소아청소년에서의 고려사항Choi Eun Hwa, Kang Hyun Mi, Kim Yae-Jean대한소아감염학회 · Pediatric Infection and Vaccine2021 · 제28권 제1호Obesity Is a Related Factor With Severe COVID-19 Pneumonia in Children: A Case Series서지현, 전경녀, Kim Dong Joon, Park Su Eun, Song EunHyang대한소아감염학회 · Pediatric Infection and Vaccine2022 · 제29권 제2호2009 Influenza A H1N1 감염 중 소아 중증 환자에 대한 고용량 Oseltamivir 투여 효과김자경, 민세라, 안성연, 양정희, 이준호, 이현수, 조현석대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2014 · 제2권 제1호

이 간행물의 다른 논문 (5건)

해외 주요 국가의 5-11세 소아 코로나19 예방접종 정책 동향최윤영, 문지현, 최영준pp. 16-275-11세 소아에서 코로나19 백신의 효능 및 안전성에 대한 체계적 문헌고찰정채림, 유수연, 최미영, 최수한, 최영준pp. 28-36국내 5-11세 소아의 코로나19 백신 접종에 대한 델파이 연구최영준, 최재홍, 이영화pp. 37-45Intraventricular Antimicrobial Therapy for Intractable Ventriculitis: Two Case ReportsYoon Yoonsun, Kim Sang-Dae, 이지원, Kim Yun-Kyungpp. 46-53Nontyphoidal Salmonella Meningitis in an Immunocompetent ChildHan Mi Seon, Moon Hye Jeong, Lee Yoonhapp. 54-60
원문 보기